Search results

After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

Result type

Technology appraisal guidance

Published

24 September 2003

Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.

Result type

Technology appraisal guidance

Published

23 February 2011

Discontinued Reference number: GID-TAG418

Result type

Technology appraisal guidance

Status

Discontinued

Discontinued Reference number: GID-TA10332

Result type

Technology appraisal guidance

Status

Discontinued

Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.

Result type

Technology appraisal guidance

Published

26 March 2025

Any explanatory notes(if applicable) Why this is important:- Before rituximab, it was accepted that high-grade transformation of...

Result type

Research recommendation

Published

25 August 2016

Past technology appraisal appeals and decisions

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

Result type

Technology appraisal guidance

Published

4 June 2025

Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

Result type

Technology appraisal guidance

Published

26 March 2025

Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.

Result type

Technology appraisal guidance

Published

17 November 2021

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

Result type

Technology appraisal guidance

Published

2 October 2019

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.

Result type

Technology appraisal guidance

Published

28 February 2023

This guidance has been updated and replaced by NICE technology appraisal guidance 243.

Result type

Technology appraisal guidance

Published

27 September 2006

This guidance has been updated and replaced by NICE technology appraisal guidance 195.

Result type

Technology appraisal guidance

Published

22 August 2007

Discontinued Reference number: GID-TA10869

Result type

Technology appraisal guidance

Status

Discontinued